abstract |
The disclosure provides methods of treating cancer by selectively inhibiting p-S 552 -β- catenin, p-T 217 -β-catenin, p-T 332 -β-catenin, and/or p-S 675 -β-catenin production and/or activity. Such methods also and/or limit cancer-initiating cells. |